Legislation to codify the change has already been introduced into both the House of Representatives and the Senate. It explicitly permits federal funding for research on stem-cell lines derived with parental permission from embryos left over at fertility clinics and other wise slated for destruction. At least one observer has suggested that legislation expli citly approving federal funding for stem-cell research is needed to address the Dickey-Wicker amendment, a law first enacted by Congress in 1996 and renewed every year since, that prohibits federal funding of research in which embryos are created or destroyed (see Nature 457, 1068-1069; 2009 ).
Scientists and advocates say the change will speed up research on stem cells and the development of possible treatments around the world, and will help remedy what they see as the Bush administration's legacy of political interference in science. "This is the first time that the key decisions and guidelines on this issue are going to be made in Bethesda and not at 1600 Pennsylvania Avenue, " says Larry Soler, executive vice-president of the Juvenile Dia betes Research Foundation International, based in New York City. "That is what the scientific community and the patient community have been asking for. "
But there was a bittersweet taste to the victory, as scientists lamented almost a decade of delays to the research. "There's no doubt that this federal policy has really slowed the rate of progress of stem-cell research in the United For instance, Lovell-Badge collaborates on one project with NIH-funded scientists who have had to limit their work to the previously approved cell lines. More broadly, the lack of policy guidance from the NIH -normally a global science-policy leader -"has contributed to the morass of different rules adopted around the world, which in turn inhibits collaboration, goodwill and progress", Lovell-Badge adds.
Indeed, CIRM president Alan Trounson says that other nations with restrictive stemcell research policies, such as Germany, now seem to be rethinking their stance, and he predicts that the Obama administration's support for the research will accelerate this trend. Such support may also encourage wary investors and pharmaceutical companies to become more involved in funding the research, and this could benefit both the biotechnology industry and the development of new treatments.
"Since Obama was elected, the pharmaceutical industry is clearly much more interested in stem cells, " Trounson says. "That will be a really big help when we're working through costly and difficult clinical trials to get treatments to patients. " But because only a few drugs can currently be selected on the basis of specific mutations, "you have to be careful with raising expectations with that kind of approach", says Marc Ladanyi, chief of molecular diagnostics at the Memorial Sloan-Kettering Cancer Center.
Anna Barker, deputy director of the National Cancer Institute in Bethesda, is optimistic that treatment options won't stay limited for long. Genomic data being gathered from patients with cancer should help researchers to identify the genetic signatures that correlate with different symptoms or rates of disease progressionand hence guide the development of drugs. Barker predicts that these signatures will also be used in the future to help doctors to combine existing drugs to target multiple genetic pathways and attack specific attributes of each patient's cancer. "I'm very optimistic that we can move in this direction, and it should be a more costeffective and better way of taking care of cancer patients," she says. 
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